 OSAKA, Japan CAMBRIDGE, Mass.BUSINESS WIRETakeda TSE:4502NYSE:TAK today announced that EXKIVITY mobocertinib has been approved by the National Medical Products Administration NMPA of China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer NSCLC with epidermal growth factor receptor EGFR Exon20 insertion mutations, whose disease has progressed on or ...... 